Within-patient fluctuation of brain volume estimates from short-term repeated MRI measurements using SIENA/FSL
暂无分享,去创建一个
Roland Opfer | Maria Pia Sormani | Ann-Christin Ostwaldt | Christine Walker-Egger | Sven Schippling | Praveena Manogaran | M. Sormani | R. Opfer | S. Schippling | Nicola De Stefano | A. Ostwaldt | Christine Walker-Egger | Praveena Manogaran | N. de Stefano
[1] K. Schmierer,et al. Is it time to target no evident disease activity (NEDA) in multiple sclerosis? , 2015, Multiple sclerosis and related disorders.
[2] L. Jones,et al. B2 Cell-based assays of CAG repeat instability in the huntingtin (HTT) gene , 2016 .
[3] Otto W. Witte,et al. Changes in Brain Size during the Menstrual Cycle , 2011, PloS one.
[4] Anisha Keshavan,et al. Intra- and interscanner variability of magnetic resonance imaging based volumetry in multiple sclerosis , 2016, NeuroImage.
[5] M. Battaglini,et al. Establishing pathological cut-offs of brain atrophy rates in multiple sclerosis , 2015, Journal of Neurology, Neurosurgery & Psychiatry.
[6] S. Vos,et al. Reliability of brain volume measurements: A test-retest dataset , 2014, Scientific Data.
[7] H. Huppertz,et al. Atlas based brain volumetry: How to distinguish regional volume changes due to biological or physiological effects from inherent noise of the methodology. , 2016, Magnetic resonance imaging.
[8] Saurabh Jain,et al. Reliable measurements of brain atrophy in individual patients with multiple sclerosis , 2016, Brain and behavior.
[9] Mark Jenkinson,et al. Optimizing parameter choice for FSL-Brain Extraction Tool (BET) on 3D T1 images in multiple sclerosis , 2012, NeuroImage.
[10] M. Sormani,et al. Estimates of age-dependent cutoffs for pathological brain volume loss using SIENA/FSL—a longitudinal brain volumetry study in healthy adults , 2017, Neurobiology of Aging.
[11] Nick C. Fox,et al. Longitudinal and cross-sectional analysis of atrophy in Alzheimer's disease: Cross-validation of BSI, SIENA and SIENAX , 2007, NeuroImage.
[12] Ludwig Kappos,et al. Correlation between brain volume loss and clinical and MRI outcomes in multiple sclerosis , 2015, Neurology.
[13] F. Barkhof. Brain atrophy measurements should be used to guide therapy monitoring in MS – NO , 2016, Multiple sclerosis.
[14] D. Arnold,et al. Correlation between brain volume change and T2 relaxation time induced by dehydration and rehydration: Implications for monitoring atrophy in clinical studies , 2014, NeuroImage: Clinical.
[15] D. Chard,et al. Grey matter pathology in clinically early multiple sclerosis: Evidence from magnetic resonance imaging , 2009, Journal of the Neurological Sciences.
[16] M. Dwyer,et al. Brain atrophy measurements should be used to guide therapy monitoring in MS – YES , 2016, Multiple sclerosis.
[17] W. Heindel,et al. Dehydration confounds the assessment of brain atrophy , 2005, Neurology.
[18] Roland Opfer,et al. Global and regional annual brain volume loss rates in physiological aging , 2017, Journal of Neurology.
[19] K. Ohtomo,et al. A longitudinal study of brain volume changes in normal aging. , 2012, European journal of radiology.
[20] M. Barnett,et al. Effect of Fingolimod on Brain Volume Loss in Patients with Multiple Sclerosis , 2017, CNS Drugs.
[21] F. Barkhof,et al. The SIENA/FSL whole brain atrophy algorithm is no more reproducible at 3T than 1.5T for Alzheimer׳s disease , 2014, Psychiatry Research: Neuroimaging.
[22] Stephen M. Smith,et al. Accurate, Robust, and Automated Longitudinal and Cross-Sectional Brain Change Analysis , 2002, NeuroImage.
[23] John G. Csernansky,et al. Open Access Series of Imaging Studies (OASIS): Cross-sectional MRI Data in Young, Middle Aged, Nondemented, and Demented Older Adults , 2007, Journal of Cognitive Neuroscience.